BioTime, a clinical-stage biotechnology company focused on degenerative diseases, has announced a new strategic alignment between AgeX Therapeutics and Juvenescence, for which the company will receive $21.6M in cash and $21.6M in a 7% convertible/redeemable note for 14.4M shares of AgeX Therapeutics.
Japanese pharmaceutical company Daiichi Sankyo and clinical-stage immuno-oncology firm Glycotope have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC).
Eli Lilly and Company has extended its cancer research collaboration with Dana-Farber Cancer Institute for three more years.
Kite and Gadeta have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers.
Cambrex has agreed to acquire contract development and manufacturing organization (CDMO) Halo Pharma for about $425m.
Novartis has agreed to make an upfront payment of EUR95m to Galapagos and MorphoSys to in-license IL-17C compound for atopic dermatitis.
Otsuka Pharmaceutical has agreed to acquire clinical-stage biotechnology firm Visterra for around $430m.
BioCryst Pharmaceuticals has failed to get approval from the stockholders for its merger deal with Idera Pharmaceuticals.
Biopharmaceutical firm Amryt has secured approval for funding from NHS England for its bad cholesterol treatment, Lojuxta (lomitapide).
Axovant Sciences has entered into a global licensing agreement with Benitec Biopharma for BB-301 (AXO-AAV-OPMD) platform to treat oculopharyngeal muscular dystrophy (OPMD).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.